Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort-Reference-Cited by-同舟云学术

Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort

Published:2021-10 Issue: Volume:96 Page:103422
ISSN:0955-3959
Container-title:International Journal of Drug Policy
language:en
Short-container-title:International Journal of Drug Policy

Author:

Carson Joanne M.,Hajarizadeh Behzad,Hanson Josh,O'Beirne James,Iser David,Read Phillip,Balcomb Anne,Davies Jane,Doyle Joseph S.,Yee Jasmine,Martinello Marianne,Marks Philippa,Dore Gregory J.,Matthews Gail V.

Funder

Abbott Diagnostics

Merck

Australian Government

Roche

Department of Health and Ageing, Australian Government

Bristol-Myers Squibb

Australian Government Department of Health

GlaxoSmithKline

Gilead Sciences

Publisher

Elsevier BV

Subject

Health Policy,Medicine (miscellaneous)

Reference16 articles.

1. Real-world efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs delivered in a multidisciplinary setting;Alimohammadi;Open Forum Infectious Diseases,2018

2. Clinicians’ views of heaptitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs;Asher;Substance Use & Misuse,2016

3. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review;Bajis;International Journal of Drug Policy,2017

4. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia;Bajis;International Journal of Drug Policy,2018

5. Sexually transmitted hepatitis C infection: The new epidemic in MSM?;Bradshaw;Current Opinion in Infectious Diseases,2013

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reinfection After Hepatitis C Virus Treatment—Keep Testing, Keep Treating;JAMA Network Open;2024-08-26

2. Hepatitis C (HCV) Reinfection and Risk Factors among Clients of a Low-Threshold Primary Healthcare Service for People Who Inject Drugs in Sydney, Australia;Viruses;2024-06-13

3. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions;The Lancet Gastroenterology & Hepatology;2024-04

4. Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret®) Example;Infectious Diseases and Therapy;2024-03

5. Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study;Canadian Liver Journal;2023-07-26